Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02999009 · ClinicalTrials.gov registry record · NA
Trident II Tritanium Acetabular Shell Outcomes Study
A NA study of Arthroplasty, Replacement, Hip, sponsored by Stryker Orthopaedics.
- Active
- Registry status
- NA
- Development phase
- 383
- Enrollment target
- 9
- Study locations
NCT02999009: Active NA study of Arthroplasty, Replacement, Hip, sponsored by Stryker Orthopaedics.
NCT02999009 is a NA study of Arthroplasty, Replacement, Hip that is active but no longer recruiting, run by Stryker Orthopaedics. The registered enrollment target is 383 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02999009, a NA study of Arthroplasty, Replacement, Hip, is active but no longer recruiting, sponsored by Stryker Orthopaedics.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 383 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to review the performance and success rate of an FDA approved cementless hip replacement part called the Trident II Tritanium Acetabular Shell. The study will specifically look at the need to revise the hip replacement after 5 years. This will be compared to how much this happens in patients who have hip replacement with similar cementless acetabular shells.
Primary Outcome
To demonstrate that acetabular replacement with the Trident II Tritanium Acetabular Shell provides clinical results comparable to similar acetabular components.
Conditions Studied
Interventions
- DEVICE Trident II Tritanium Acetabular Shell
Study Locations (9)
New York
- Hospital for Special Surgery - New York
- Northwell Health, Lenox Hill Hospital - New York
Arizona
- Tucson Orthopaedic Institute - Tucson
Florida
- Southeast Orthopedic Specialists - Jacksonville
Illinois
- American Hip Institute - Des Plaines
Louisiana
- Center for Orthopaedics and Spine, LLC - Lake Charles
Michigan
- St. Joseph Mercy Hospital Health System - Ypsilanti
New Jersey
- Rothman Institute - Egg Harbor
North Carolina
- UNC Orthopaedics - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2017-01-20 |
| Est. Completion | 2031-03 |
| Phase | NA |
What the registry record for NCT02999009 still lists
NCT02999009 is an interventional study that assigns participants to a tested intervention. The registered 383 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Arthroplasty, Replacement, Hip appearing as the primary indexed condition, and to 1 intervention - of which Trident II Tritanium Acetabular Shell is the first listed.
NCT02999009 lists 9 locations in 8 states (New York, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT02999009 about?
NCT02999009 is a clinical study titled "Trident II Tritanium Acetabular Shell Outcomes Study". The purpose of this study is to review the performance and success rate of an FDA approved cementless hip replacement part called the Trident II Tritanium Acetabular Shell. The study will specifically look at the need to revise the hip replacement after 5 years. This will be compared to how much thi...
What is the current status of trial NCT02999009?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 383 participants. The study started on 2017-01-20. Estimated completion is 2031-03.
What conditions does trial NCT02999009 study?
This clinical trial studies the following conditions: Arthroplasty, Replacement, Hip.
What interventions are being tested in trial NCT02999009?
The interventions under investigation include: Trident II Tritanium Acetabular Shell (DEVICE).
Who is sponsoring clinical trial NCT02999009?
This trial is sponsored by Stryker Orthopaedics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02999009 being conducted?
This trial has 9 study locations across Arizona, Florida, Illinois, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthroplasty, Replacement, Hip
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02999009's enrollment target sits among peer trials
383 273rd of 2000 higher than 1,728 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06056830 · 383 participants · Phase 3
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- NCT06277661 · 384 participants · NA
The Mom and Infant Outcomes (MOMI) Study
- NCT06372964 · 384 participants · Phase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- NCT06501040 · 384 participants · NA
Increasing Knowledge and Interest in Cancer Clinical Trials
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI